Evidence map›Paper›PMID 39763588›Full record

ArticleFrontiers in cell and developmental biology2024

PLK1 inhibition impairs erythroid differentiation.

Peijun Jia, Yan Li, Lulu Duan, Jingxin Zhang, Yuanlin Xu, Huan Zhang, Chenghui Wang, Yaqian Gong, Ying Zhang, Longzhen Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peijun Jia *School of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yan Li *School of Life Sciences, Zhengzhou University, Zhengzhou, China.
Lulu DuanSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Jingxin ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yuanlin XuDepartment of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Huan ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Chenghui WangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yaqian GongSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Ying ZhangSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Longzhen ZhaoSchool of Life Sciences, Zhengzhou University, Zhengzhou, China.
Yumin Huang *Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shijie Zhang *School of Life Sciences, Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polo-like kinase 1 (PLK1), a key regulator of the G2/M phase in mitosis, is frequently overexpressed in numerous tumors. Although PLK1 inhibitors have emerged as promising therapeutic agents for cancer, their use has been linked to significant anemia in a subset of patients, yet the underlying mechanisms remain poorly understood. In this study, we utilized an

Indexed as

anemiaapoptosiscell cycleerythropoiesisplk1

Identifiers

PMID39763588
PMCPMC11701054

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.